Freedom of Information Request: Our Reference CTMUHB_496_23

You asked:

Please see below a Freedom of Information request. Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

Patients with acute myeloid leukaemia (AML)

1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?
    - Azacitidine monotherapy
    - Low dose cytarabine (LoDAC) monotherapy
    - Venetoclax + azacitidine
    - Venetoclax + LoDAC
    - Ivosidenib
    - Intensive chemotherapy-based regimen
    - Other

    Answer:

2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?
    - Azacitidine monotherapy
    - Low dose cytarabine (LoDAC) monotherapy
    - Venetoclax + azacitidine
    - Venetoclax + LoDAC
    - Ivosidenib
    - Intensive chemotherapy-based regimen
    - Other

    Note: this should only include patients who have started first-line treatment during the 6-month window

    Answer:

3. Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many received treatment in line with National Institute for Health and Care Excellence guidance?

    Answer:

Patients with chronic lymphocytic leukaemia (CLL)

4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

    Note: this should include patients who started treatment prior to the 6-month window

    Answer:

5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

   Note: this should include only patients who have started treatment during the 6-month window

   Answer:

Our response:

We do not centrally record this information. Our dispensing system does not differentiate between indications or line of treatment

The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.